THE TRENDLINES GROUP LTD.
(Incorporated in Israel)
(Company Registration No. 513970947)

INVESTMENTS BY LH RELATED COMPANIES IN PORTFOLIO COMPANIES OF THE COMPANY

The Board of Directors of The Trendlines Group Ltd. ("**Trendlines**" or the "**Company**" and, together with its subsidiaries and associated companies, the "**Group**") wishes to announce that the Audit Committee and the Board of Directors of Trendlines have approved investments in Trendlines' portfolio companies Ceretrieve Ltd. ("**Ceretrieve**") and Vensica Medical Ltd. ("**Vensica**") by related companies of Librae Holdings Limited ("**LH**" and such related companies known as "**LH Related Companies**").

LH is deemed, according to the Listing Manual, Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (the "**Catalist Rules**") and the Israeli Companies Law for interested party transactions ("**IPTs**"), to be the controlling shareholder of Trendlines.

The LH Related Companies are ultimately owned by a trust of which Mr. Vincent Tchenguiz ("**Mr. Tchenguiz**") is the discretionary beneficiary. Mr. Tchenguiz is also deemed to be a controlling shareholder of Trendlines under the Catalist Rules and for IPTs under the Israeli Companies Law.

LH Related Companies are ultimately held by Geneva Trust Company (GTC) SA as Trustees of The VT Two Trust. As stated above, LH is deemed a controlling shareholder of Trendlines under the Catalist Rules and is ultimately held by Geneva Trust Company (GTC) SA as Trustees of The Tchenguiz Three Trust. Mr. Tchenguiz is the discretionary beneficiary of both The VT Two Trust and The Tchenguiz Three Trust.

As part of the Group's ongoing efforts to develop its portfolio companies, attract strategic investors and position them for successful exits, the Group continues to seek co-investment from supportive shareholders and strategic partners. In this regard, the Audit Committee and the Board of Directors of Trendlines have approved the following investments in the Group's portfolio companies by LH Related Companies, alongside the Company's own co-investments ("**Investment**"):

Portfolio Company	LH Related Companies ('000 USD)	Trendlines ('000 USD)	Transaction Type
Ceretrieve	$250	$250	SAFE(1)
Vensica	$600	$300	SPA(2)
Total	$850	$550	

(1) The investment will be in the form of a Simple Agreement for Future Equity ("**SAFE**") transaction. A SAFE is an equity derivative instrument, by which the SAFE investor commits capital to an investee company today, in exchange for the right to receive shares in the portfolio company when there is a future financing round by the portfolio company.

(2) The investment is in the form of a share purchase agreement ("**SPA**"), in which LH Related Companies will subscribe for shares of the portfolio company, joining existing financing rounds of the portfolio company.

Neither LH Related Companies nor Mr. Vincent Tchenguiz possess any influence on the terms of the investments.

The above transactions met all the required pre-requisite conditions, including the execution of the definitive agreement by Trendlines, LH Related Companies and the respective portfolio company, and obtaining necessary approvals from the respective portfolio companies' board of directors.

The Investments by LH Related Companies and Trendlines as detailed above are on normal commercial terms and are not prejudicial to the interests of Trendlines and its minority shareholders. The Investments will not result in a change in the fair value of Trendlines' holdings in the portfolio companies or the consolidated Net Tangible Assets of the Group. As such, the Investments will not have a material effect on the consolidated earnings per share and net tangible assets per share of the Group for the financial year ending 31 December 2026.

The Board wishes to highlight that the participation of LH Related Companies as a co-investor has strengthened the Group's ability to attract additional external and strategic investors into its portfolio companies, thereby enhancing their competitiveness and improving potential exit outcomes. The additional capital from these Investments will provide the portfolio companies with further financial resources to support their ongoing operations, research and development efforts, and clinical trials, bringing them one step closer towards achieving successful exits.

The Board is of the view that such continued co-investment support is beneficial to, and not prejudicial to, the interests of the Company and its minority shareholders.

BY ORDER OF THE BOARD
Haim Brosh
Executive Director and Chief Executive Officer
11 May 2026

---

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.